Literature DB >> 19690030

Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.

Florian Eckel1, Ken Herrmann, Stefan Schmidt, Claudia Hillerer, Hinrich A Wieder, Bernd-Joachim Krause, Tibor Schuster, Rupert Langer, Hans-Jürgen Wester, Roland M Schmid, Markus Schwaiger, Andreas K Buck.   

Abstract

UNLABELLED: We determined the ability of PET with the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) to detect hepatocellular carcinoma (HCC).
METHODS: In this pilot study, (18)F-FLT PET was performed in 18 untreated patients with clinically suspected HCC. Routine diagnostic procedures included ultrasound, MRI, or contrast-enhanced spiral CT of the upper gastrointestinal tract in all patients. At 45-60 min after the intravenous injection of approximately 270-340 MBq of (18)F-FLT, emission and transmission scanning was performed with a high-resolution PET scanner. Tracer uptake in the tumor and surrounding liver tissue was evaluated semiquantitatively by calculation of mean and maximum standardized uptake values (SUVs). Results were correlated with those of the conventional imaging methods.
RESULTS: A total of 13 of 18 tumors (sensitivity, 72%; 95% confidence interval [CI], 47%-90%) showed focal (18)F-FLT uptake higher than surrounding liver activity and were detectable as hot lesions. Five tumors were characterized as photopenic lesions or contained a mixture of hot and cold lesions exhibiting a comparable or lower (18)F-FLT uptake than the surrounding liver tissue. When all lesions were considered, the mean (18)F-FLT SUV was 7.8 (range, 2.5-11.1), and the maximum (18)F-FLT SUV was 9.3 (range, 2.9-14.3). Histology and clinical follow-up revealed HCC in 16 patients and cholangiocarcinoma in 2 patients. In the subgroup of HCC, the sensitivity for tumor detection was 69% (11/16; 95% CI, 41%-89%). Correlation analysis demonstrated a significant positive relationship between the proliferation marker MIB-1 and the mean SUV (r = 0.66, P = 0.02). Survival analysis (Cox proportional hazards regression) for initial (18)F-FLT uptake (mean and maximum SUVs) revealed increased hazard ratios (mean SUV, 1.20; maximum SUV, 1.12), but because of the small number of events, these results were not statistically significant.
CONCLUSION: In this pilot study, HCC tumors showed a mixed uptake pattern for the in vivo proliferation marker (18)F-FLT. A total of 69% of the HCC lesions showed (18)F-FLT uptake higher than that of the surrounding liver tissue, whereas the remaining lesions were photopenic or contained a mixture of hot and cold lesions. High initial (18)F-FLT uptake seems to be associated with reduced overall survival and could be an important prognostic factor if this tendency can be confirmed in a larger prospective trial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690030     DOI: 10.2967/jnumed.109.065896

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

Review 1.  The emerging role of positron emission tomography in hepatocellular carcinoma.

Authors:  Suraiya R Dubash; Oluwagbemiga A Idowu; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-04-27

2.  A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.

Authors:  Esther Mena; Maria Liza Lindenberg; Baris I Turkbey; Joanna Shih; Jean Logan; Stephen Adler; Karen Wong; Wyndham Wilson; Peter L Choyke; Karen A Kurdziel
Journal:  Clin Nucl Med       Date:  2014-10       Impact factor: 7.794

3.  3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.

Authors:  Jeong Eun Kim; Sun Young Chae; Jwa Hoon Kim; Hwa Jung Kim; Tae Won Kim; Kyu-Pyo Kim; Sun Young Kim; Jae-Lyun Lee; Seung Jun Oh; Jae Seung Kim; Jin-Sook Ryu; Dae Hyuk Moon; Yong Sang Hong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-30       Impact factor: 9.236

4.  The potential use of 2-[¹⁸F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma.

Authors:  Michael Sørensen; Kim Frisch; Dirk Bender; Susanne Keiding
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

5.  ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.

Authors:  Flavio Crippa; Roberto Agresti; Marco Sandri; Gabriella Mariani; Barbara Padovano; Alessandra Alessi; Giulia Bianchi; Emilio Bombardieri; Ilaria Maugeri; Mario Rampa; Maria Luisa Carcangiu; Giovanna Trecate; Claudio Pascali; Anna Bogni; Gabriele Martelli; Filippo de Braud
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

Review 6.  New approaches for precise response evaluation in hepatocellular carcinoma.

Authors:  Koichi Hayano; Jorge M Fuentes-Orrego; Dushyant V Sahani
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

7.  Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation.

Authors:  Jae Seon Eo; Jin Chul Paeng; Dong Soo Lee
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  Comparison of the [18F]-FDG and [18F]-FLT PET Tracers in the Evaluation of the Preclinical Proton Therapy Response in Hepatocellular Carcinoma.

Authors:  David Brasse; Hélène Burckel; Patrice Marchand; Marc Rousseau; Ali Ouadi; Marie Vanstalle; Christian Finck; Patrice Laquerriere; Frédéric Boisson
Journal:  Mol Imaging Biol       Date:  2021-04-13       Impact factor: 3.488

Review 9.  Functional imaging techniques in hepatocellular carcinoma.

Authors:  V Goh; D Sarker; S Osmany; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-21       Impact factor: 10.057

10.  Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma.

Authors:  Patricia Larsson; Dag Arvidsson; Mikael Björnstedt; Bengt Isaksson; Ulf Jersenius; Hooman Motarjemi; Hans Jacobsson
Journal:  Mol Imaging Radionucl Ther       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.